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ABSTRACT  52 
 53 
Most of the posterior segment diseases are chronic and multifactorial and require long-term 54 
intraocular medication. Conventional treatments of these pathologies consist of successive 55 
intraocular injections, which are associated with adverse effects. Successful therapy requires 56 
the development of new drug delivery systems able to release the active substance for a long 57 
term with a single administration. The present work involves the description of a new generation 58 
of microspheres based on poly (ester amide)s (PEA), which are novel polymers with improved 59 
biodegradability, processability and good thermal and mechanical properties. We report on the 60 
preparation of the PEA polymer, PEA microspheres (PEA Ms) and their characterization. PEA 61 
Ms (~15 µm) were loaded with a lipophilic drug (dexamethasone) (181.0 ± 2.4 µg DX/mg Ms). 62 
The in vitro release profile of the drug showed a constant delivery for at least 90 days. Based on 63 
the data from a performed in vitro release study, a kinetic ocular model to predict in vivo drug 64 
concentrations in a rabbit vitreous was built. According to the pharmacokinetic simulations, 65 
intravitreal injection of dexamethasone loaded PEA microspheres would provide release of the 66 
drug in rabbit eyes up to 6 months. Cytotoxicity studies in macrophages and retinal pigment 67 
epithelial cells revealed a good in vitro tolerance of the microsystems. After sterilization, PEA 68 
Ms were administered in vivo by subtenon and intravitreal injections in male Sprague-Dawley 69 
rats and the location of the microspheres in rat eyes was monitored. We conclude that PEA Ms 70 
provide an alternative delivery system for controlling the delivery of drugs to the eye, allowing a 71 
novel generation of microsphere design.  72 
 73 
GRAPHICAL ABSTRACT  74 
 75 
 76 
 77 
 78 
KEYWORDS Ocular drug delivery; microspheres; poly(ester amide); tolerance; 79 
dexamethasone; intraocular injection. 80 
  81 
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INTRODUCTION 82 
 83 
Most of diseases affecting the posterior segment of the eye are related with visual impairment 84 
and blindness. The effective treatment of these pathologies is one of the major challenges in 85 
drug delivery as most of them are chronic and multifactorial. Among them, aged-related macular 86 
degeneration, diabetic retinopathies and glaucoma produce irreversible visual damage and 87 
blindness [1]. These diseases are becoming more and more prevalent in the aging populations, 88 
and nowadays tens of millions of patients are affected worldwide. Depending on the disease, 89 
the medications should be delivered to the retinal cells, retinal pigment epithelium or choroid. 90 
Furthermore, therapeutic concentrations of the active substance in the intraocular target site 91 
have to be maintained during a long period of time. 92 
 93 
Due to the ocular barriers, it is difficult to deliver effective drug concentrations to the posterior 94 
tissues of the eye using non-invasive routes such as topical or systemic administration [2]. It is 95 
well known that after topical administration only very low drug concentrations are reached in the 96 
retina and choroid [3]. This is due to the obstacles of drug penetration that include the short 97 
residence time of formulations on the ocular surface, the presence of tissue barriers (cornea, 98 
lens, conjunctiva, sclera), and flow mediated drug loss factors (conjunctival blood flow, aqueous 99 
humor flow) that limit the drug access to the retina and choroid. Although systemic 100 
administration is used to deliver some drugs to the eye (e.g. corticosteroids), this route is 101 
restricted by the systemic toxicity of the drugs and reduced access to the target site, mainly due 102 
to the blood-aqueous and blood-retinal barriers [2].  103 
 104 
The most effective method of drug delivery to the back of the eye is through intraocular 105 
administrations, mainly intravitreal injections. However, intravitreal administration is an invasive 106 
mode of drug delivery and it is sometimes associated with adverse effects (endophthalmitis, 107 
hemorrhages, damage of lens or retinal detachment) and it requires frequent visits of the 108 
patients to the clinics. Besides, most low molecular weight drugs have short intravitreal half-lives 109 
(2-10 hrs), so they have to be administered frequently to be clinically feasible. Controlled drug 110 
delivery systems, such as nano- and microcarriers, as well as implants, able to release and 111 
maintain effective active substance levels over long periods of time, would prolong the dosing 112 
interval to months [4, 5]. Biodegradable micro- and nanoparticulate systems are emerging 113 
therapeutic tools as they can be administered as a conventional injection by periocular 114 
(subconjunctival, subtenon, juxtascleral) and intraocular routes and they are cleared from the 115 
site of administration over time.  116 
 117 
Ophthalmic drug delivery systems can be made with a variety of biodegradable materials such 118 
as polyesters (lactide and glycolide copolymers, polycaprolactones, poly(β-hydroxybutyrates)), 119 
polyamides (including natural polymers such as collagen, gelatin and albumin), 120 
heteropolysaccharides (chitosan) or lactic and glycolic acid polymers and copolymers, among 121 
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others. Poly-lactic-co-glycolic acid (PLGA) has been widely used for the development of a 122 
number of drug delivery systems, such as the intraocular commercialized implant loaded with 123 
dexamethasone (Ozurdex®).  The advantages of biodegradable implants over the non-erodible 124 
devices in the clinical practice have promoted the interest in novel polymers adequate for 125 
intraocular drug delivery purposes.  126 
 127 
We have studied a new generation of microspheres based on poly(ester amide)s (PEA). The 128 
PEAs are amino acid containing biodegradable polymers combining ester and amide groups in 129 
the polymer chain. This chemical structure contributes to improved biodegradability, 130 
processability and mechanical properties of the materials (via intra- or inter-chain hydrogen 131 
bonding interactions though its amide groups). Furthermore, an important polymer feature is 132 
that the current composition of PEA predominantly degrades through surface erosion 133 
mechanism [6]. These materials have already demonstrated good biocompatibility showing little 134 
or no inflammation both in vitro and in vivo [7] including in an ophthalmic setting [8]. Extruded 135 
PEA fibrils have been implanted in both periocular (subconjunctival) and intravitreal routes in a 136 
rabbit experimental model. Readouts after 1, 3, 5 days and 2, 4, 8 weeks have shown excellent 137 
material tolerance and tissue biocompatibility. Further work [9] investigated blood and cellular in 138 
vitro responses of PEA. The findings of the study revealed that monocytes adherent to PEA 139 
secreted reduced levels of the pro-inflammatory interleukins (IL)-6 and IL-1β into the culture 140 
supernatant relative to those on comparative polymers but secreted significantly higher amounts 141 
of the anti-inflammatory mediator, IL-1 receptor antagonist. A PEA coating on cardiovascular 142 
stent has been reported in a phase III, 2-armed clinical study [10]. The 24-months follow up of 143 
this study reports absence of Major Adverse Cardiac Events (MACE) and suggests that the 144 
tested PEA-coated stent is safe [11].  145 
 146 
The present work is focused on the study of the ability of biodegradable polyesteramide to form 147 
microspheres for ophthalmic drug delivery purposes. Microspheres present several advantages 148 
among other ophthalmic drug delivery forms for different reasons: (a) Drugs encapsulated in 149 
microspheres are protected from degradation and physiological clearance, (b) the release 150 
kinetics of the drug can be adjusted by varying the technological parameters of these systems 151 
and (c) microspheres can be injected as a suspension using conventional needles (27-34G) 152 
without surgery [12].  153 
 154 
This study shows the synthesis of polyesteramide (PEA) polymers and the preparation, 155 
sterilization, “in vitro tolerance” and delivery characteristics of microspheres (Ms) made from 156 
PEA and loaded with a lipophilic drug model (dexamethasone).  After studying the impact of 157 
gamma sterilization on the properties of these systems, we have built a kinetic ocular model 158 
with in vitro release data to predict in vivo drug concentrations in a rabbit vitreous model. Then, 159 
we studied the impact of the different reagents, solutions and processes required to perform 160 
histological procedures, on the properties of Ms, in order to establish the most appropriate 161 
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inclusion techniques for in vivo studies. Finally, we have analyzed the behavior of PEA Ms after 162 
injection in the subtenon space and in the vitreous humor of rats with the aim of determining 163 
whether or not a satisfactory amount of PEA Ms were placed in the desired locations. 164 
 165 
MATERIAL AND METHODS 166 
 167 
Material 168 
 169 
Polyvinyl alcohol 67 kDa (PVA) was provided by Merck (Darmstadt, Germany). Acetonitrile 170 
(ACN), dichloromethane (DCM) and methanol (MET) were purchased from Sigma-Aldrich 171 
(Schenelldorf, Germany). Tetrahydrofuran (THF) was supplied by Teknokroma (Barcelona, 172 
Spain). Super gradient acetonitrile (ACN) was purchased from Lab-Scan (Madrid, Spain). 173 
Dexamethasone (DX), dimethyl sulphoxide (DMSO) and 3-(4-5-dimethylthiazol-2-yl)-2,5-174 
diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (Schnelldorf, Germany). 175 
Freshly produced MilliQ water (W) was used in all the experiments. Poly-(D,L-lactide-co-176 
glycolide) PLGA ratio 50:50 (35 kDa; Resomer 503) was purchased from Boehringer Ingelheim 177 
GmbH (Ingelheim am Rhein, Germany). Polyvinyl alcohol 72 kDa (PVA) and anhydrous DMF 178 
were obtained by Merck KGaA (Darmstadt, Germany). Polyethyleneimine (PEI) microspheres 179 
were supplied by Micromod (Rostok, Germany). Unless noted otherwise, cell culture reagents 180 
were provided by Life Technologies (Carlsbad, CA, USA). Macrophages (RAW 264.7) and 181 
human retinal pigment epithelial cell lines (ARPE-19) were obtained from the American Type 182 
Culture Collection (ATCC, Manassas, VA, USA). 183 
 184 
Synthesis of polyesteramide copolymers  185 
 186 
The polymer in this study is a biodegradable poly(ester amide) based on α-amino acids, 187 
aliphatic dicarboxylic acids and aliphatic α-ω diols. Among this class of materials the AA-BB 188 
hetero-chain polymers offer the greatest versatility in terms of molecular level design to tailor 189 
drug release properties. The selected PEA is depicted on Fig. 1 and it comprises three type of 190 
building blocks randomly distributed along the polymer chain.  191 
 192 
 193 
Figure 1 Structure of PEA III Ac Bz. 194 
The polymer was synthesized according to a procedure reported previously [13]. Briefly, the 195 
polymer was prepared via solution polycondensation of di-p-toluenesulfonic acid salts of bis-(α-196 
amino acid) α,ω-diol diesters, lysine benzyl ester and di-N-hydroxysuccinimide sebacate in 197 
anhydrous DMF. The use of pre-activated acid in the reaction allows polymerization at low 198 
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temperature (650C) affording side-product free polycondensates and predictable degradation 199 
products [14]. The polymer was isolated from the reaction mixture in two precipitation steps. The 200 
polymer was characterized by 1H NMR spectroscopy and THF based GPC relative to 201 
polystyrene standards. 202 
 203 
Polymer characterization  204 
 205 
1H NMR spectra were obtained on a Bruker Avance 500 MHz Ultrashield NMR; samples were 206 
recorded in ethanol d6.  207 
 208 
Molecular weight and molecular weight distributions of PEA were determined by GPC equipped 209 
with RI detector. Samples were dissolved in THF at a concentration of approximately 5 mg/mL 210 
and were run at a flow rate of 1 mL/min at 50 ºC. The molecular weights were calibrated to a 211 
narrow polystyrene standard calibration curve, using Waters Empower software. 212 
 213 
Preparation of microspheres  214 
 215 
PEA microspheres (PEA Ms) were prepared via the emulsion solvent-evaporation technique. 216 
Briefly, 2 mL of an organic phase composed of PEA/DCM (15%) was emulsified with 5 mL of an 217 
aqueous solution of PVA (2%) at 8,500 rpm for 1 min (Polytron PT 3000, Kinematica, Lucerna, 218 
Switzerland). This emulsion was subsequently poured onto 100 mL of an aqueous solution of 219 
PVA (0.1%) and kept under constant stirring for 4 hours, to allow organic solvent evaporation 220 
and hardening of microspheres. After this process, PEA Ms were washed and filtered at low 221 
temperature (4ºC). After that, microspheres were suspended in 1 mL of an aqueous solution of 222 
mannitol (2%), used as cryoprotectant. The resulting suspension was freeze-dried. Ms were 223 
kept at 4ºC in desiccators until use. To prepare dexamethasone-loaded PEA microspheres (DX-224 
PEA Ms), 60 mg of DX were dispersed by gentle sonication (Sonicator XL, Head Systems, 225 
Iowa, USA) in 2 mL of the organic phase composed of PEA/DCM (15% w/v), for 3 minutes. 226 
Then, microspheres were prepared following the same steps described above. All the 227 
procedure was performed protecting dexamethasone from exposure to light. The percentage 228 
yield of each batch was calculated.  229 
 230 
To help identify the location of the microspheres in ocular tissues after in vivo injections, a PEA 231 
polymer that contained 0.02 % w/w chromoionophore II (absorption: 520-600nm, emission: 232 
660nm Fluka, Sigma-Aldrich, Schnelldorf, Germany) was employed. The dye molecule was 233 
incorporated to the polymer by dissolving of a calculated amount of chromoionophore II in 10 % 234 
polymer solution in ethanol. Later the solvent was evaporated and obtained material was used 235 
for preparation of microspheres. For the in vitro tolerance studies, microspheres composed of 236 
PLGA were used as reference of a non-toxic polymeric material. Both, fluorescent PEA Ms and 237 
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PLGA Ms, were prepared with techniques based on the emulsion-solvent evaporation method 238 
described above.  239 
 240 
Quantification of dexamethasone  241 
 242 
Dexamethasone was quantified by high performance liquid chromatography (HPLC) using a 243 
liquid chromatograph with a pump M520, a UV detector M490E, an autosampler 712D WTSP 244 
and the Empower Login HPLC System Manager Software, all by Waters (MA, USA). The 245 
chromatographic separation was achieved with a C18 column Tracer Excel 120 ODSA (particle 246 
size 5 µm, 150 mm x 4mm; Teknokroma, Barcelona, Spain). The mobile phase flow was set at 247 
1 mL/min and the injection volume was 20 µL. The absorbance of the eluent was monitored at 248 
254 nm. All the analyses were performed at 45 ± 0.5ºC.  249 
 250 
The composition of the mobile phase A was methanol:ACN:water (3:3:4). The mobile phase B 251 
was composed of 100% ACN. Both A and B were vacuum-filtered through 0.45 µm nylon 252 
millipore membrane (Merck, Darmstadt, Germany), and degassed by ultrasonication for 15 253 
minutes before use (Elma Transsonic 460, Singen, Germany). A gradient elution method was 254 
employed and the chromatograph was programmed as follows: 100% A for 10 min, followed by 255 
0 to 100% B over 15 min, then 100 to 0% B over 5 min and finally 100% A over 5 min. The 256 
HPLC method was validated with respect to linearity, accuracy and reliability in the range of 257 
concentrations of 2-20 µg/mL.  258 
 259 
 260 
Microsphere characterization 261 
 262 
Microspheres’ morphology was evaluated by scanning electron microscopy (SEM; Jeol JSM-263 
6335F, Tokyo, Japan). Before examination, samples were sputter coated with gold.  264 
 265 
Mean particle size and particle size distribution were measured by light scattering in a Microtrac 266 
S3500 Series Particle Size Analyzer (Montgomeryville, PA, USA). Samples were analyzed by 267 
dispersing the microspheres in MilliQ Water. Data are presented as mean volume diameter ± 268 
standard deviation of three independent measurements.  269 
 270 
To determine the encapsulation efficiency of DX, 5 mg of solid DX-PEA Ms were dissolved with 271 
200 µL DCM. Then, 800 µL of ACN were added and, after strong mixing by vortex for 2 min, the 272 
solution was centrifuged at 15,000 rpm (4ºC, 15 min). The supernatant was further removed, 273 
filtered (0.45 µm membrane) and analyzed by HPLC, following the method described above. 274 
The entrapment efficiency was determined by using the formula: drug entrapment efficiency = 275 
(experimental drug content/theoretical drug content) x 100. 276 
 277 
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The chemical stability of PEA during the microsphere fabrication process was evaluated by 278 
high-performance gel permeation chromatography (GPC). To this, microspheres were dissolved 279 
in THF (1 mg/mL). Then, samples were filtered with a PTFE membrane (0.2 µm). Two columns 280 
PGgel 3 µm MIXED-E and PGgel 5 µm MIXED-D, both of 7.8 mm x 300 mm (Varian, Polymer 281 
Laboratories, Church Stretton, UK), were connected in series to increase the accuracy of the 282 
procedure. The equipment consisted of a Waters 1525 binary HPLC pump and a Waters 2414 283 
Refractive Index Detector (Waters, Saint-Quentin en Yvelines, France). The flow rate was set to 284 
1 mL/min of THF, and temperature of the process was 33ºC. Prior to measurements, the GPC 285 
columns were calibrated with polystyrene standards of molar masses: 381, 1100, 2950, 6520, 286 
18,600 and 43,700 g/mol, supplied by Waters (Mainz, Germany) and 10,100, 24,600 and 287 
72,450 g/mol, purchased from Varian (Polymer Laboratories, Church Stretton, Shrosphire, UK).  288 
 289 
Sterilization of microspheres 290 
 291 
Microspheres were sealed in glass vials and irradiated with 60Co (Gamma Sterilization Unit of 292 
Aragogamma S.A., Barcelona, Spain) at low temperature (-80ºC). Following the USP 293 
recommendations, a dose of 25 kGy was applied to ensure an effective sterilization [15]. 294 
Sterilized formulations were characterized as described above.  295 
 296 
In vitro release studies  297 
 298 
Solid DX-PEA Ms (5 mg) were incubated in 1.5 mL of a phosphate buffered solution isotonized 299 
with sodium chloride (PBS, pH 7.4; with KH2PO4 1.54 mM, Na2HPO4-7H2O 2.71 mM and NaCl 300 
155.17 mM). Samples were placed in a shaker at a constant agitation speed of 100 rpm (NE5 301 
Shaking Water Batch, Nikel Electro Ltd., Weston-super-Mare, United Kingdom) at 37ºC. At pre-302 
set times (1 h, 24 h and twice every week during 90 days) the supernatant was recovered and 303 
replaced with the same volume of fresh PBS. Supernatant was analyzed by HPLC to determine 304 
the amount of released DX. Studies were performed under sink conditions and in triplicate. 305 
Microsphere’ morphology was analyzed with SEM during the first two weeks. Sterilized and non-306 
sterilized DX-loaded microspheres’ release profiles were compared with the evaluation of the 307 
similarity factor f2 [16].  308 
 309 
Kinetic modeling of dexamethasone release from microspheres 310 
 311 
A kinetic ocular model was built, in order to predict dexamethasone concentrations in the rabbit 312 
vitreous during drug delivery from the PEA microspheres. The simulations were carried out with 313 
Stella software (ISEE systems 10.0). Firstly, the in vitro release data of dexamethasone was 314 
used to define the release rate of dexamethasone from the microspheres using curve fitting. 315 
This represents drug release in sink conditions (y = M0 + M1 log(x), where x = time and y = 316 
released dexamethasone (%).  M0 = 18.19 and M1 = 18.5 (R2 = 0.9425).  317 
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Secondly, the model for in vivo delivery of dexamethasone was built (Fig. 2) and different 318 
dexamethasone doses (100-1000 µg) were used to simulate drug concentration in the vitreous 319 
after microsphere administration.  320 
 321 
Figure 2 Ocular model of vitreal dexamethasone after its release from the PEA microspheres. 322 
A: released dexamethasone amount in the vitreous, Vd: volume of distribution, CLivt: clearance 323 
of dexamethasone from the vitreous.  324 
 325 
Drug release was defined as k = (release rate in vitro * (Cs – Cvitreous) / Cs), where Cs = 326 
dexamethasone solubility in water (0.089 mg/mL at 25 °C, Drug Bank) and Cvitreous = free drug 327 
concentration in the vitreous (µg/mL). Dexamethasone concentrations in the vitreous were 328 
simulated using the aforementioned formulation parameters and pharmacokinetic parameters of 329 
dexamethasone in the rabbit eyes (CLivt = 0.668 ml h-1, volume of distribution, Vd = 1.5 mL) [17]. 330 
Vd was estimated based on the previous report that demonstrates narrow range of intravitreal Vd 331 
values of ocular drugs [29]. CLivt of dexamethasone was calculated using the QSPR model for 332 
intravitreal drug clearance in the rabbit vitreous [29]. The calculation is as follows: LogCLivt= -333 
0.25269 - 0.53747 (LogHD) + 0.05189 (LogD7.4). Dexamethasone is within the applicable 334 
chemical space of the model (supplementary material).   335 
 336 
In vitro tolerance of microspheres  337 
 338 
Cytotoxicity studies were performed with two cell lines: mouse macrophages (RAW 264.7) and 339 
retinal pigment epithelial cells (ARPE-19). In vitro citotoxicity was assessed using mitochondrial-340 
dependent reduction of the tetrazolium salt, 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 341 
bromide (MTT) to formazan.  342 
 343 
RAW 264.7 cells were maintained in RPMI 1640 medium (Life Technologies) supplemented 344 
with 10% fetal bovine serum (FBS) and 2% penicillin/streptomycyn, and placed onto 24-well 345 
plates (9.5 x 104 cells/well). After an incubation period of 4 hours (37ºC and 5% CO2), the media 346 
was changed to RPMI supplemented with 2% FBS, and cells were exposed to microspheres 347 
dispersed in DPBS for 20 hours. Then, the medium was carefully removed and the cells reacted 348 
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with MTT (5 mg/mL in PBS) for 3 hours at 37ºC. The reaction product, formazan, was extracted 349 
with DMSO. The extent of the reduction of MTT to formazan within cells was quantified by the 350 
measurement of optical density at 550 nm, using a microplate reader (model 6010152EU; 351 
DigiScan, Eugendorf, Austria). Microspheres’ dispersions were tested in the range 0.001-2 352 
mg/mL. PEI microspheres (8 µm size) were used as positive control and PLGA microspheres 353 
(20 µm size) as reference of a non-toxic material. Microspheres were dispersed with HBSS 354 
(without Ca2+ or Mg2+) in all cases. Assays were performed in triplicate and results are 355 
expressed as percent of reduction in cell viability compared to vehicle-treated cells for at least 356 
three independent experiments.  357 
 358 
Human retinal pigment epithelial cells (ARPE-19) were cultured in a Dulbecco’s modified 359 
Eagle’s medium (DMEM): Nutrient Mixture F12, 1:1 mixture, supplemented with 10% heat 360 
inactivated FBS, 2 mM L-Glutamine, 50 U/mL streptomycin and 50 U/mL penicillin. The cells 361 
were maintained at 37 ºC in a humidified atmosphere containing 7% CO2. For the cytotoxicity 362 
assay, ARPE-19 cells were seeded on a 24-well plate one day prior to the experiment day at a 363 
density of 80 000 cells/well. On the day of experiment, PEA microspheres and PLGA 364 
microspheres in HBSS buffer (without Ca2+ or Mg2+) were incubated with the ARPE-19 cells, at 365 
a concentration of 0.1 – 2 mg/mL. Poly-L-lysine (15-30 kDa, Sigma-Aldrich, MO, USA) in DPBS 366 
buffer (without Ca2+ or Mg2+) was used as a positive reference polymer in the assay, at a 367 
concentration of 0.001 – 2 mg/mL. After 5 hour of incubation, the wells were washed and 368 
replaced with supplemented growth medium. On the third day, 24 hours later, MTT in serum-369 
free growth medium was added to the cells (0.5 mg/mL). MTT is converted to a water-insoluble 370 
formazan by mitochondrial activity of living cells. The formazan crystals were solubilised with 371 
10% sodium dodecyl sulphate (Bio-Rad, Ca, USA) - hydrochloric acid and on the fourth day the 372 
optical density was measured at 570 nm (VarioSkan Flash, Thermo Scientific, Madrid, Spain). 373 
The percentage cell viability was calculated by comparing the viability of the PEA and PLGA 374 
microspheres or PLL treated cells with HBSS or DPBS treated cells, respectively. Cytotoxicity 375 
data was obtained from at least three different experiments or more, by testing triplicate wells 376 
per sample. 377 
 378 
Handling of microspheres for in vivo injections  379 
 380 
Unloaded PEA Ms and dye-loaded PEA Ms suspended in PBS were analyzed under both, light 381 
and fluorescence optic microscopy. In order to ascertain the most appropriate techniques for in 382 
vivo biocompatibility assessment, solid PEA Ms were exposed to reagents (4% 383 
paraformaldehyde, 2% glutaraldehyde, xylene, EtOH and acetone), solutions (distilled water 384 
and PBS) and processes (freezing at -20ºC and heating at 60ºC) required to perform 385 
histological procedures, specifically paraffin and epoxy resins embedding and tissue frozen. For 386 
that, 100 µL of the reagents and solutions were added to the PEA Ms powder and kept in 387 
contact with them from 5 minutes to 5 hours.  388 
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 389 
In vivo injections 390 
 391 
Animals and anaesthetics 392 
 393 
Rats were treated in accordance with the Spanish Laws and the Guidelines for Human 394 
Endpoints for Animals Used in Biomedical Research. This study was approved by the Ethics 395 
Committee for Animal Research of Complutense University of Madrid. Also, animal 396 
manipulations followed institutional guidelines, European Union regulations for the use of 397 
animals in research, and the ARVO (Association for Research in Vision and Ophthalmology) 398 
statement for the use of animals in ophthalmic and vision research.  399 
 400 
The experiments were performed on adult male Sprague-Dawley rats (250 g) obtained from 401 
Harlan Laboratories (Udine, Italy). The animals were housed in temperature- and light-402 
controlled rooms with a 12h light/dark cycle and ad libitum access to food and water. Light 403 
intensity within the cages ranged from 9 to 24 lux. All surgical procedures were performed under 404 
general anaesthesia induced with an intraperitoneal (i.p.) injection of a mixture of Ketamine (75 405 
mg/kg, Ketolar®, Parke-Davies, S.L., Barcelona, Spain) and Xylazine (10 mg/kg, Rompún®, 406 
Bayer, S.A., Barcelona, Spain). During recovery from anaesthesia, rats were placed in their 407 
cages, and an ointment containing tobramycin (Tobrex®; Alcon S.A., Barcelona, Spain) was 408 
applied on the cornea to prevent corneal desiccation and infection. Additional measures were 409 
taken to minimize discomfort and pain after ocular injection.  410 
 411 
Intraocular injection 412 
 413 
To ensure appropriate and reproducible intraocular injection of the PEA Ms, freshly prepared 414 
microsphere suspensions in Balanced Salt Solution (BSS; Alcon, TX, USA) were released 415 
through different gauge needles (25G, 27G, 30G and 32G). Microspheres were quantified in a 416 
Neubauer chamber cell counting (BLAUBRAND® counting chambers, Germany) by using the 417 
manual counting tool of the Metamorph Imaging System. To analyse whether time elapsed 418 
between PEA Ms suspension preparation and injection influences microsphere behaviour, the 419 
Neaubauer cell counting chamber was loaded with PEA Ms suspensions by using a 30G needle 420 
5, 20, 30, 60, 90, 120 and 180 minutes after microsphere suspension preparation.  421 
 422 
In order to analyze PEA Ms behavior in vivo and to ascertain that a satisfactory amount of PEA 423 
Ms were placed in the desired location, rat eyes were injected periocularly (subtenon space) 424 
and intraocularly (vitreous) and then processed for histological study. For that, the rats were 425 
divided into two groups: intravitreal injection (n= 21) and subtenon injection (n=33). In both 426 
cases, the right eye of each animal was injected under general anesthesia with blank PEA Ms 427 
and fluorescent PEA Ms suspended in PBS. The injections were done with a 30G without dead 428 
12 
 
space volumen needle fitted to a sterilized 10 µL (for intravitreal) or 25 µL (for subtenon) low 429 
dead space Hamilton syringe. For intravitreal injections 1, 2 or 3 µL of PEA Ms suspension were 430 
injected just behind the limbus to avoid damaging the lens. For subtenon injections 25 µL of the 431 
PEA Ms suspension were injected in the superotemporal quadrant. The intraocular pressure 432 
(IOP) of the rats was measured under deep anaesthesia in both eyes with a rebound tonometer 433 
(Tono-Lab, Tiolat, OY, Helsinki, Finland) prior and after PEA Ms injection. Animals were 434 
sacrificed at two time points: immediately and 24 hours after microsphere injection.  435 
 436 
Before and after injection, clinical evaluation of the rat eyes were done under a surgical 437 
microscope (Leica M 500-N, Leica Microsystems, Schweiz AG) by two independent 438 
ophthalmologist in a masked procedure. At each examination the conjunctiva, cornea, anterior 439 
chamber, lens, vitreous and retina were examined. Clinical signs were recording according to a 440 
scoring system. At each examination the intraocular pressure was measured while rats were 441 
under deep anesthesia. At all time points, 3 to 4 consecutive readings were perforemed for 442 
each eye and were averaged. 443 
 444 
Tissue processing 445 
 446 
The rats were deeply anaesthetized, perfused transcardially through the ascending aorta first 447 
with saline and then with 4% paraformaldehyde in 0.1 M phosphate buffer (PBS, pH 7.4). The 448 
animals were sacrificed with an intraperitoneal overdose of pentobarbital (Dolethal Vetoquinol®, 449 
Especialidades Veterinarias S.A., Alcobendas, Madrid, Spain). The orientation of each eye was 450 
carefully maintained with a suture placed on the superior pole immediately after deep 451 
anaesthesia and before perfusion fixation. Moreover, upon dissection of the eye, the insertion of 452 
the rectus muscle and the nasal caruncle were used as additional landmarks. The eyes were 453 
post-fixed for 2h in the same fixative and kept in sterile 0.1 M PBS. Subtenon injected eyes 454 
were processed for cryosections and eyes receiving intravitreal injection for both, cryosections 455 
and as retinal whole-mounts.  For cryosections, the lenses were removed and the eye cups 456 
were cryoprotected by overnight incubation in 30% sucrose at 4ºC, after which they were 457 
embedded in Tissue-TeK O.C.T compound. For retinal-whole mount the cornea, iris and lens 458 
were removed and the retinas extracted from the resulting eye cup.  459 
 460 
Localization of microspheres after subtenon and intravitreal injections  461 
 462 
In order to analyze PEA Ms behavior and to ascertain their ocular location after injection, the 463 
retinal whole-mounts and some cryosections were observed unstained (mounted with 464 
PBS/glycerol) both, under light and fluorescence microcopy. In addition, some cryosections 465 
were stained with hematoxylin-eosin (HE), dehydrated and mounted with water-free mounting 466 
medium (DPX. Merck, Germany). 467 
 468 
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Ocular tissues were analysed and photographed with an imaging microscope (Axioplan 2; 469 
Zeiss, Göttingen, Germany) equipped with appropriate filters for fluorescence-emission spectra 470 
of 515/65 nm (Filter set 17, Zeiss), 647/70 nm (Filter set 64, Zeiss) and 445/45 nm (Filter set 49, 471 
Zeiss) and Nomarski Interference Contrast illumination technique. 472 
 473 
RESULTS 474 
 475 
Polymer characterization  476 
 477 
The obtained PEA product was of number average molecular weight (Mn) of 49 kDa and narrow 478 
dispersity index (ĐM) as revealed by GPC analysis (Table 1). 479 
 480 
 481 
Table 1 Polymer characterization 482 
 483 
 Mn (kDa) Glass transition temperature ĐM 
PEA  49 49 0C 1.56 
 484 
 485 
The 1H NMR spectrum was in full agreement with the anticipated chemical structure of the 486 
polymer. The 1H NMR spectrum of the purified polymer is in agreement with the chemical 487 
structure as shown in Figure 3.  488 
 489 
 490 
 491 
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Figure 3 1H NMR spectrum recorded in deuterated ethanol, 500 MHz. The NMR data are in full 492 
agreement with the anticipated chemical structure of the polymer. 493 
 494 
The aromatic signals 14 at 7.35-7.25 ppm correspond well to aliphatic multiplet at 3.20-3.10 495 
ppm indicating no side ester groups have been lost in the polycondensation reaction. The signal 496 
of protons 4 shifted to lower field than protons 7. This allows differentiating between the amide 497 
linkages involving alpha and epsilon amino groups in the polymer chain. The characteristic 498 
chemical shifts for 1,6-hexanediol (m, 4.20-4,05 ppm), lysine (m, 3.20-3.10 ppm) and 1,4:3,6-499 
Dianhydro-D-sorbitol (s, 4.80 ppm) allow for determination of  the relative molar ratio of the 500 
amino acid containing building blocks (Fig 3). The results confirmed the very good agreement 501 
between actual and theoretical copolymer composition. The 1H NMR spectrum further actual 502 
relative ratio between ester and amide bonds in the polymer chain to be calculated which is 503 
1:1.33. 504 
 505 
Microspheres characterization 506 
 507 
The linearity of the method used to quantify dexamethasone was linear over the range 2-20 508 
µg/mL (intercept -46395, slope 355329, coefficient of determination 0.999). Accuracy ranged 509 
between 98.4 and 101.3%, and intra- and interday precision determined by percent coefficient 510 
of variation, was 2.18% and 2.16%, respectively.  511 
 512 
The microencapsulation procedure used led to a high yield in all cases (79.1 ± 6.15%).  513 
Microsphere’ morphology examined by SEM revealed spherical particles with no pores and 514 
smooth surface (Fig 4). The mean particle size obtained ranged from 10-20 µm (15.0 ± 6.4 µm 515 
for blank PEA Ms and 14.2 ± 6.1 µm for DX-PEAIII Ms). The encapsulation efficiency of DX was 516 
85.1 ± 0.9% (181.0 ± 2.4 µg DX/mg Ms). The number average molecular weight of PEA Ms was 517 
similar to the one found for the raw PEA material (Mn=48.3 ± 3.7 KDa for blank PEA Ms and 518 
Mn=49.2 ± 1.4 KDa for DX-PEAIII Ms). 519 
 520 
Sterilization of microspheres 521 
 522 
The morphology of microspheres was not modified by the sterilization procedure (Fig. 4) and no 523 
changes in the mean particle size were detected (15.2 ± 6.6 µm for blank PEA Ms and 15.0 ± 524 
6.1 µm for DX-PEAIII Ms). Sterilization by γ-irradiation did not modify the drug content (183.2 ± 525 
1.6 µg DX/mg Ms, p=0.86). Furthermore, solubility of the polymeric particles in THF did not 526 
change as well suggesting that the gamma irradiation at the sterilization conditions does not 527 
result in polymer branching or crosslinking. The GPC results revealed a minor change in the 528 
polymer molecular weight. The Mn of the polymer sample after sterilization was 14 % lower than 529 
the sample analyzed before gamma-irradiation suggesting limited chain cleavage. 530 
 531 
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In vitro release studies  532 
 533 
The release rate of DX from sterilized and non-sterilized microspheres is shown in Fig 5. For 534 
non-sterilized microspheres, the release profile was characterized by an initial burst of 17.7 ± 535 
0.6 µg DX/mg Ms (9.7 ± 0.3%) released in the first 24 h, followed by a short rapid release period 536 
of one week and a second long period of slow release up to 90 days. The cumulative DX 537 
release at day 90 was 53.9 ± 5.7% of the encapsulated drug (97.8 ± 11.1 µg DX/mg Ms). The 538 
release profile of sterilized and non-sterilized Ms showed similar results since the calculated 539 
similarity factor f was 98.3, which indicates that the average difference between the two release 540 
profiles was no more than 2%.  541 
 542 
 543 
 544 
Figure 4 SEM images and particle size distribution of non-sterilized (a, c and e) and sterilized 545 
(b, d and f) DX-loaded PEA microspheres. 546 
 547 
 548 
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 549 
 550 
Figure 5 Cumulative percent of dexamethasone released versus time of non-sterilized (-■-) and 551 
sterilized (-o-) PEA microspheres. PBS was used as release media (pH 7.4, 37ºC).  552 
 553 
Microspheres only kept their spherical morphology during the first day after incubation in PBS. 554 
Then, a morphological change was produced and microspheres remodeled to an unshaped 555 
depot (Fig. 6). 556 
 557 
 558 
 559 
Figure 6 SEM images of PEA microspheres incubated in PBS, at different time points: (a) 560 
before incubation, (b) t=1 hour, (c) 24 hours, (d) 3 days, (e) 1 week and (f) 2 weeks. 561 
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 562 
Kinetic modeling of dexamethasone release from microspheres 563 
 564 
A pharmacokinetic model was built in order to predict dexamethasone concentration in rabbit 565 
vitreous during dexamethasone release from the PEA microspheres. Fig. 7 shows comparison 566 
of the experimental in vitro release data and simulated release based on the fitting of the 567 
release data and derivatization of the fitted curves. Finally, different dexamethasone loading 568 
doses were used in the in vivo dexamethasone model (Fig. 2), in order to simulate drug 569 
concentrations in the vitreous (Table 2, Fig. 8).  570 
 571 
Figure 7 The in vitro release data (± S.D.) of dexamethasone from PEA microspheres versus 572 
the fitted dexamethasone release.  573 
 574 
Table 2 The predicted dexamethasone concentrations (µg/ml) in rabbit vitreous at different 575 
doses delivered in the microspheres.  576 
 577 
  Predicted Concentration (µg/ml) 
Dose Cmax 42 days 90 days  
100 µg 2.25 0.012 0.0055  
200 µg 4.42 0.024 0.011  
400 µg 8.53 0.048 0.023  
800 µg 15.88 0.096 0.044  
 578 
  579 
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 580 
Fig. 8. Simulated time profile for free dexamethasone in the vitreous after administration in PEA 581 
miscrospheres.  582 
 583 
Cytotoxicity 584 
 585 
In vitro cytotoxic effects of PEA microspheres in RAW 264.7 macrophages are shown in Fig 8. 586 
Cell viability was not significantly affected in the presence of different concentrations of 587 
microspheres prepared with polyesteramide polymer (PEA) or PLGA whereas, treatment with 588 
PEI microspheres, used as positive control, caused a sharp drop in cell viability at 2 mg/mL.  589 
 590 
Similarly, no signs of toxicity were seen in ARPE-19 cells after 5 hours of incubation, for both 591 
PEA and PLGA microspheres (Fig. 9) In contrast, poly-L-lysine showed high toxicity at all 592 
concentration (IC50 17.3 ± 2.3 µg/mL).  593 
 594 
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 596 
 597 
Figure 8 Effects of PEA on cell viability. RAW 264.7 cells were pre-incubated with PEA 598 
microspheres (0.001-2 mg/ml) for 20 h. Microspheres of polyethyleneimine (PEI) were used as 599 
positive control and PLGA was considered as a reference of non-toxic material. Cell viability 600 
was determined by the MTT assay. Values are expressed as mean ± coefficient of variation of 601 
three independent experiments. 602 
 603 
 604 
 605 
 606 
Figure 9 Percentage cell viability of ARPE-19 treated cell (± standard deviation). Cells were 607 
incubated with polyesteramide microspheres (PEA), poly(lactic-co-glycolic) acid microspheres 608 
(PLGA) or poly-L-lysine (PLL) for 5 h. 609 
 610 
Handling of microspheres for in vivo injections  611 
 612 
Under light microscopy PEA Ms suspended in PBS were easily visualized.  Under fluorescence 613 
microscopy, unloaded PEA Ms had autofluorescence emission in the blue, green, and red 614 
spectral regions. However, in the red spectral region the emission intensity was lower than for 615 
dye-loaded microspheres (supplementary material).. PEA Ms: i) were inert and stable when 616 
contacted with distilled water (Fig. 10A), phosphate buffered saline (Fig. 10B), 4% 617 
paraformaldehyde (Fig. 10C,D) and 2% glutaraldehyde; ii) as expected PEA particles loose 618 
shape or dissolve in contact with Xylene (Fig. 10E), EtOH (Fig. 10F) or acetone ; iii) freezing at -619 
20ºC (Fig. 10D) and heating at 60ºC does not impact particles re-dispersion, shape and 620 
polydispersity (supplementary material).    621 
 622 
 623 
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 624 
 625 
Figure 10 Effects on PEA microspheres of reagents, solutions and processes required to 626 
perform histological procedures. PEA microspheres were inert and stable when contacted with 627 
distilled water (2A), phosphate buffered saline (2B) and 4% paraformaldehyde (2C,D). In 628 
contrast, they were dissolved in contact with Xylene (2E) and EtOH (2F). They resisted freezing 629 
at -20ºC (2D). 630 
 631 
 632 
Unloaded and dye-loaded PEA Ms had a tendency to aggregate both, at the eppendorf and 633 
inside the Hamilton syringe after suspension preparation, this feature being more pronounced in 634 
the dye-loaded Ms. This tendency increased with time, being greater 30 minutes after 635 
suspension preparation. Aggregation of dye-loaded PEA Ms precluded quantification in the 636 
Neubauer chamber cell counting (Fig. 11B). For freshly suspensions of unloaded PEA Ms, no 637 
significant differences in microspheres number released through different needle gauges (25G, 638 
27G, 30G, 32G) were found (Table 3) (Fig. 11A).  However, when the elapsed time between 639 
preparation and injection was longer, a tendency to aggregate was observed in Ms, being this 640 
feature more pronounced in dye-loaded Ms, whose counting was not possible with this method 641 
(Fig 11B). So, in order to assure a proper administration, the injection of Ms should be 642 
performed during the first 30 minutes after their dispersion. 643 
 644 
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 645 
Figure 11 PEA microspheres quantification in the Neubauer chamber cell counting. The 646 
microphotographs correspond to Neubauer chamber loading through a 30G needle.  Unloaded 647 
PEA microspheres (A) counting was possible. However, the tendency of dye-loaded PEA 648 
microspheres (B) to aggregate (arrow) precluded quantification with this methodology. Light 649 
microscopy.  650 
 651 
Table 3 PEA microspheres quantification in a Neubauer chamber cell counting  652 
 653 
Needle gauge PEA microsphere number† 
25G 304.48 ± 39.35 
27G 322.80 ± 31.38 
30G 333.56 ± 39.81 
31G 316.88 ± 35.62 
† mean ± standard deviation 654 
 655 
Localization of microspheres after intravitreal and subtenon injections  656 
No clinical signs of inflammation were observed in the anterior or posterior segment of the rats 657 
after subtenon or intravitreal injection. At the two time points of sacrifice it was observed that 658 
most PEA Ms aggregate and coalesce into depots, both, in the vitreous (Fig. 12G) and in the 659 
subtenon space (Fig. 12C,D,E,F,H), that contained a large amount of Ms. Intravitreal injection of 660 
1-3µl of PEA Ms did not increased IOP.  661 
 662 
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In unstained whole-mount and cryosections (both mounted with PBS/glycerol), dye-loaded PEA 663 
Ms (Fig. 12A, B) and unloaded PEA Ms (Fig. 12E, H) preserved their morphological 664 
characteristics. However, during HE staining of the cryosections, alcohol dehydration dissolved 665 
the microspheres and a “ghost image” was observed, corresponding with the intraocular 666 
location of the microspheres (Fig. 12F). Under fluorescence microscopy, the autofluorescence 667 
of the ocular tissues hinder visualization of unloaded PEA Ms (Fig. 12H). Dye-loaded PEA Ms 668 
improved notoriously microspheres visualization (Fig. 12B,D).  669 
 670 
 671 
Figure 12 intraocular locations of dye-loaded and unloaded PEA microspheres immediately and 672 
24 hours after injection. Whole-mounts (A,B,G). Cryosections (C,D,E,F,H). Light microscopy 673 
(A,C,E,F,G). Fluorescence microscopy (B, D, F). In unstained tissues mounted with an  674 
aqueous media (A-D, F-H), PEA microspheres preserved their morphological characteristics 675 
and coalesced into depots in the two locations tested: intravitreal (A, B, G) and subtenon (C, D, 676 
F, H). Tissue dehydration required to perform hematoxylin-eosine staining dissolved the 677 
microspheres but a “ghost image” corresponding with the intraocular site of the PEA 678 
microspheres (black arrows) remains (F).  Although unloaded PEA microspheres were 679 
autoflorescent, the autofluorescence of the ocular tissues hinder unloaded PEA microspheres 680 
(white arrows) identification (H). In this regard, dye-loading (D) enhanced significantly 681 
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microsphere identification. OD: optic disc; C: conjunctiva; M muscle; R: retina; S: sclera; Ch: 682 
choroid. 683 
 684 
DISCUSSION 685 
 686 
Current developments in the therapy of ophthalmic chronic diseases are directed towards the 687 
use of new drug delivery systems that allow sustained therapeutic levels of therapeutic 688 
molecules at ocular target tissues. Due to the unique characteristics of ocular barriers, 689 
controlled drug delivery has become a challenge for scientists, especially when the target site is 690 
located in the posterior segment of the eye. Among the intraocular drug delivery systems, 691 
implants and microspheres have demonstrated to provide long term delivery of the active 692 
substance after their administration and the utility of microspheres as drug delivery systems for 693 
intraocular administration has been previously reported [18-20, 30]. One of their main 694 
advantages is that they can be administered as a conventional injection using a small gauge 695 
needle. Furthermore, depending on the patients’ needs, a properly dose of the active substance 696 
can be adjusted by administering a determined amount of microspheres, allowing a 697 
personalized therapy. In this experimental work, the use of polyesteramide polymers (PEA), a 698 
new generation of biodegradable materials, to prepare microspheres as drug delivery systems 699 
for the back of the eye, has been evaluated.  700 
 701 
PEA microspheres (Ms) were prepared with a technique based on the emulsion- solvent 702 
evaporation method. The mean particle size obtained ranged from 10 to 20 µm, suitable to be 703 
administered without surgery by conventional injection as suspension through standard needles 704 
(27-34G) [18, 19]. One of the critical aspects of drug delivery systems for the back of the eye is 705 
the tolerance. In general, cells can endocytose particles that are below 200 nm in diameter. 706 
However, macrophages and retinal pigment epithelial (RPE) cells are phagocytic cells that may 707 
take up even particles in the micrometer size range [21].  Thus, it is important to study the 708 
toxicity in these cell types that will be exposed to the particles upon their internalization. In the 709 
present work, the ARPE-19 cell line served as the model for RPE cells [22]. In vitro cytotoxicity 710 
of PEA microspheres was tested by the MTT technique with microspheres dispersed in HBSS. 711 
In a culture of macrophages (RAW 264.7), after 20 hours of exposure time, PEA Ms resulted to 712 
be well tolerated, giving viability values higher or equal to 80% at all the concentrations that 713 
were tested (0.001-2 mg/mL). Similarly, the PEA microspheres (0.1-2 mg/mL) did not show any 714 
signs of toxicity in ARPE-19 cells after 5 hours of incubation.  715 
 716 
PEA microspheres were sterilized by γ-irradiation at a dose of 25KGy [4]. Sterilization was 717 
performed at low temperature to reduce the effects on the polymer, since it is known that γ-718 
irradiation can affect the properties of bioresorbable polyesters [15]. No significant changes on 719 
the morphology of microspheres, loading and release of dexamethasone were observed due to 720 
sterilization under the conditions employed in this work. The polymer analyses confirmed that 721 
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particles sterilization under the experimental conditions results in only minor chain scission of 722 
polymer chain and do not affect important material characteristics such as morphology and 723 
solubility 724 
 725 
Pharmacokinetic simulations were conducted in order to predict the intraocular concentrations 726 
of dexamethasone during drug delivery from the PEA microspheres. In vitro release data from 727 
PEA microspheres and pharmacokinetic information from rabbit vitreous were utilized in the 728 
model. Taking into account the encapsulation efficiency of the microencapsulation procedure 729 
(181 µg dexamethasone/mg PEA microspheres), the intravitreal injection volume in rabbit (100 730 
µL) and the microsphere concentration of 25 mg/mL, the highest possible dexamethasone dose 731 
in the microsphere injection would be around 450 µg. In the simulations, 400 µg of 732 
dexamethasone resulted in Cmax of 8.5 µg/mL and the simulated concentration at 3 months was 733 
23 ng/ml. We can compare these values after Ozurdex implant delivery (700 µg 734 
dexamethasone) in cynomolgus monkeys: Cmax was 213 ± 49 ng/mL (at 60 days) and at 6 735 
months concentration was 1.3 ± 1.9 ng/mL [23]. In clinical studies Ozurdex was tolerated well 736 
and caused improvement in visual acuity for 180 days in patients with macular edema [24-26]. 737 
PEA microspheres seem maintain therapeutic dexamethasone concentrations in the vitreous for 738 
at least 3 months. Importantly, 400 µg dose of dexamethasone sodium phosphate as intravitreal 739 
solution injection in the rabbits did not cause any abnormalities during 2 months [17,27]. This 740 
suggest that the initial rapid release from dexamethasone microspheres is not expected to lead 741 
to dexamethasone borne toxicity. Intravitreal dexamethasone dose of 450 µg would require 2.2 742 
mg of PEA microspheres that would result in the maximal PEA concentration of 1.47 mg/mL in 743 
the vitreous. This concentration was safe in the cellular MTT assays, but further in vivo studies 744 
are needed to prove the duration of activity and safety of PEA microspheres with 745 
dexamethasone.   746 
 747 
In this paper PEA Ms compatibility with the steps required for intraocular and periocular injection 748 
(known routes to deliver drugs to the posterior segment of the eye) [28] has been studied in 749 
detail. Furthermore, the polymer interaction with histological analysis reagents has been 750 
investigated as first step of comprehensive biocompatibility assessment. Several reagents are 751 
required for presevering (fixative solutions) and sectioning the tissues (embedding techniques) 752 
during histological processing. PEA Ms were compatible with the two main fixatives used in 753 
histology, paraformaldehyde (for light microscopy) and glutaraldehyde (for electron microscopy). 754 
 755 
PEA Ms loose shape or dissolved during the dehydration steps required for paraffin and epoxy 756 
resin embedding techniques. Therefore, cryosections seems to be the most suitable method for 757 
PEA Ms visualization under light microscopy. Although PEA Ms can be easily recognized in 758 
unstained sections mounted with an aqueous media, biocompatibility assays require tissue 759 
staining. The present study reveals that staining techniques including dehydration in their 760 
protocols (i.e., HE used in the present study) affect PEA Ms. Thus, in order to analyze PEA Ms 761 
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biocompatibility, consecutive unstained (mounted with PBS/glycerol) and stained cryosections 762 
must be simultaneously analyzed; the former for microsphere location and the latter for tissue 763 
tolerability analysis.  764 
 765 
PEA Ms can be released into ocular tissues through different gauge needles (25G, 27G, 30G 766 
and 32G). Given that no significant differences in the number of PEA Ms were found between 767 
the different needles gauges analyzed, a 30G was selected for intraocular injection as it is the 768 
most frequently used in human clinical settings. Due to the tendency of microspheres to 769 
aggregate (Fig. 3A), injection during the first 30 minutes following suspension preparation 770 
assured a properly administration. The most appropriate volume of PEA Ms for intravitreal 771 
injection in rats was 3 µl, since this volume achieves enough amounts of microspheres in the 772 
vitreous humor without increased IOP. Twenty four hours after intraocular injection both dye-773 
loaded PEA Ms and unloaded PEA Ms retain their morphology and coalesce into depots in the 774 
vitreous and in the subtenon space. Such depots contained a large amount of Ms suggesting 775 
that the PEA Ms are able to reach properly the injection site. Chromoionophore II-containing 776 
PEA Ms were not suitable for in vivo assays given that due to their great tendency to aggregate, 777 
it is not possible to ascertain that a sufficient and reproducible number of Ms reach the injection 778 
space.   779 
 780 
CONCLUSIONS  781 
 782 
Amino acid based polyesteramides were successfully formulated into microspheres (~15 µm), 783 
which showed good in vitro tolerance with macrophages and retinal pigment epithelial cells. The 784 
microspheres can be readily sterilized by gamma irradiation and administered using 27-32G 785 
needles within 30 min of suspension preparation. Loading and release studies with 786 
dexamethasone revealed high drug encapsulation efficiency (~85%) with a controlled delivery 787 
for 90 days. Pharmacokinetic simulations indicate that these microspheres would provide a 788 
release of the drug in rabbit eyes up to 3 months. After 24 hours, the injected PEA Ms retain 789 
their morphology and coalesce into depots in the vitreous and in the subtenon space. The large 790 
amount of Ms located into the depots suggested that PEA Ms were able to reach properly the 791 
injection site. It can be concluded that these polyesteramide microspheres provide an 792 
alternative delivery system for controlled delivery of drugs to the eye. 793 
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Supplementary material 917 
 918 
 919 
Supplemental figure The PCA score plot of the training set of the intravitreal clearance model 920 
{{del Amo et al. 2015, http://dx.doi.org/10.1016/j.ejpb.2015.01.003 }}. The full triangles show the 921 
chemical space of the compounds that were used to train the model. Dexamethasone is inside 922 
the chemical space ellipse indicating that the model is applicable for dexamethasone. 923 
 924 
 925 
 926 
 927 
 928 
Supplemental figure Unloaded PEA microspheres. Morphological appearance under 929 
fluorescence (A-C) and light (D) microscopy. PEA microspheres had autofluorescence emission 930 
in the green (A), red (B) and blue (C) spectral regions. Nomarski interference contrast (D).  931 
 932 
  933 
30 
 
Supplemental table PEA microspheres preservation after 5 minutes of contact with reagents 934 
and solutions used in common tissue staining methods. Light microscopy. Regents and 935 
solutions assayed did not affect the autoflourescence properties of the unloaded PEA 936 
microspheres.  937 
 938 
Reagents and solutions* PEA microsphere preservation** 
Distilled wáter +++ 
Phosphate buffered saline +++ 
EtOH 100% - 
Acetone - 
Xylene - 
4% PF ++++ 
2% Glutaraldehyde 2% ++++ 
4% PF (5 min) + EtOH 100% ± 
4% PF (5 min) + Xylene  ± 
4% PF (5 min) + EtOH (5 min) + Xylene ± 
2% Glutaraldehyde (5 min) + Acetone ± 
 939 
*100 µl of the reagent were added to the microsphere powder. **Subjective grading scale 940 
ranging from microsphere shape unaffected (++++) to microsphere dissolved (-). [PBS: 941 
Phosphate buffered saline; PF: paraformaldehyde 942 
 943 
 944 
 945 
Supplemental table  scoring system used to evaluate the rat eyes 946 
 947 
Conjunctival Hyperemia  
No reaction, normal vessels, 0 
Definitely injected vessels /Mild hyperemia 1 
Diffuse crimson red / Intense  2 
Diffuse beefy red  3 
Conjunctival Swelling  0 
No reaction 1 
Mild edema 2 
Intense edema 3 
Cornea  
Normal cornea 0 
Scattered o diffuse areas of opacity (Details of iris clearly visible) 1 
Details of iris slightly obscured 2 
31 
 
No details of iris visible, size of pupil barely discernible  3 
Opaque cornea: iris no discernible through the opacity 4 
Anterior chamber haze  
Details of iris clearly visible 0 
Details of iris slightly obscured 1 
No details of iris visible, size of pupil barely discernible  2 
Opaque cornea: iris no discernible through the opacity 3 
Lens  
Clear 0 
Cataract 1 
Vitreous  
Absence of inflammation 0 
Isolated cells that allow to visualize the main vessel 1 
Mild to moderate haze with most of the retina obscured 2 
Severe haze and infiltration of the retina totally obscured 3 
Retinal detachment  
Absence 0 
Presence 1 
Retinal and vitreous hemorrhages  
Absence 0 
Presence 1 
*Modified from Einmahl, 2001; Rincon, 2006 and  Diebold, 2007 948 
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